Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

After a nurse died after just two weight-loss injections of Mounjaro - which is approved for use on the NHS - here's ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Jim Gaffigan reveals his weight loss journey with Mounjaro tackling food addiction and societal stigma while balancing comedy ...

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

At my worst, I smoked 20 cigarettes a day. So my reaction on hearing the news of a daily pill, to be handed out free on the ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Jim Gaffigan has always used his weight and love for eating as a punchline in his comedy, even going so far to title his 2013 ...

Regulatory watchdog South African Health Products Regulatory Authority said these types of products pose a health risk to the public.